JUVÉDERM Products for Midface Volume Loss
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and effectiveness of different JUVÉDERM products to improve facial volume and skin quality. JUVÉDERM, a type of filler, can make areas like the cheeks, lips, and chin appear fuller and smoother. Suitable candidates for this trial often feel their face looks less full or sags, particularly around the cheeks, jawline, or lips. Participants should be in good health and should not have received similar treatments in the past year. As a Phase 4 trial, this research involves an FDA-approved treatment, aiming to understand its benefits for more patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial organizers or your doctor.
What is the safety track record for these JUVÉDERM treatments?
A previous study found JUVÉDERM products to be generally well-tolerated for restoring facial volume and improving skin quality. These treatments use hyaluronic acid, a substance naturally found in the body, to smooth wrinkles and add volume.
The FDA has approved JUVÉDERM VOLUMA XC for treating temple hollowing, confirming its safety for that purpose. SKINVIVE by JUVÉDERM also holds FDA approval for improving cheek smoothness, further supporting its safety.
Most people using JUVÉDERM products experience only minor side effects, such as swelling or redness at the injection site. These effects typically resolve on their own. The products have been widely used and are considered safe for cosmetic treatments.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about JUVÉDERM products for midface volume loss because they offer a more customizable and potentially longer-lasting solution compared to traditional fillers. Unlike standard options that often require frequent touch-ups, JUVÉDERM products use advanced hyaluronic acid formulations designed to provide natural-looking volume with improved longevity. Additionally, the variety of products like VOLUMA XC and VOLUX XC allows for tailored treatment plans, addressing specific needs and achieving desired aesthetic outcomes more precisely.
What evidence suggests that JUVÉDERM products are effective for midface volume loss?
Research has shown that JUVÉDERM products effectively treat facial volume loss. In this trial, participants will receive at least two JUVÉDERM products for at least three indications, with specific products and indications determined by the investigator. JUVÉDERM VOLUMA XC adds volume to the cheeks and improves the appearance of the chin. Studies have found that JUVÉDERM ULTRA XC fills deeper wrinkles and enhances lip fullness. These fillers contain hyaluronic acid, a natural substance in the skin, to create a fuller, smoother appearance. JUVÉDERM products are widely used and trusted for enhancing facial volume and reducing wrinkles.46789
Who Is on the Research Team?
ABBVIE INC.
Principal Investigator
AbbVie
Are You a Good Fit for This Trial?
Adults with varying degrees of facial volume loss who wish to improve their facial appearance can join this trial. They must have specific levels of hollowing, wrinkles, or folds according to Allergan's scales and be in good health as determined by medical history and exams.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive at least 2 JUVÉDERM products for at least 3 indications at Treatment Visit 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- JUVÉDERM ULTRA PLUS XC
- JUVÉDERM ULTRA XC
- JUVÉDERM VOLBELLA XC
- JUVÉDERM VOLLURE XC
- JUVÉDERM VOLUMA XC
- JUVÉDERM VOLUX XC
- SKINVIVE by JUVÉDERM
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois